Search

Displaying results 1251 - 1260 of 1723 in total
  1. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis.

  2. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]

  3. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence

  4. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    [A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual

  5. Drug

    Trimetazidine

    go.drugbank.com/drugs/DB09069
    ApprovedInvestigational

    [A233215] Trimetazidine is not FDA approved. However, it has been approved in France since 1978.[L33020]

  6. Drug

    Eluxadoline

    go.drugbank.com/drugs/DB09272
    ApprovedInvestigational

    Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms

  7. Drug

    Secnidazole

    go.drugbank.com/drugs/DB12834
    ApprovedInvestigational

    [A245503, A245508] In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.[L39524]

  8. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. … Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.

  9. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    It was granted Fast Track status for this indication by the FDA in November 2004.

  10. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    It was granted FDA orphan designation in November 2018.[L47067]